pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one, VX-702 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide), LY2228820 (5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine; methanesulfonic acid), VX-745 (5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one) or PH-797804 (3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxopyridin-1-yl]-N,4-dimethylbenzamide).

13. The method according to any one of the preceding claims, wherein the serum-free and insulin-free medium of step (iii) comprises the p38-MAPK inhibitor SB203580.

14. The method according to any one of the preceding claims, wherein the medium of step (iv) comprises 0.5 to 5 % serum.

15. The method according to any one of the preceding claims, wherein the medium of step (iv) comprises 0.5%, 1%, 1.5%, 2% , 2.5%, 3%, 3.5%, 4%, 4.5% or 5% serum.

16. The method according to any one of the preceding claims, wherein the medium of step (iv) comprises 2% serum.

17. The method according to any one of the preceding claims, wherein the serum comprises fetal bovine serum (FBS).

18. The method according to any one of the preceding claims, wherein the induced pluripotent stem cells comprises human induced pluripotent stem cells.

19. A population of cells comprising mesenchymal stem cell-like cells and cardiomyocyte-like cells obtained by the method according to claim 1 or 2.

20. An isolated population of cells comprising cardiomyocyte-like cells obtained by the method according to any one of claims 3, or 7 to 9.

21. An isolated population of cells comprising mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 6.

22. A composition comprising at least one isolated population of mesenchymal stem cell-like cells according to any one of claims 3 to 5 and at least one isolated population of cardiomyocyte-like cells obtained by the method according to any one of claims 3 or 7 to 8.

23. A kit comprising at least one population of cells according to any one of claims 19 to 21 or the composition according to claim 22.

24. A population of cells comprising mesenchymal stem cell-like cells and cardiomyocyte-like cells obtained by the method according to claim 1 or 2, for use in cell replacement.

25. An isolated population of cells comprising cardiomyocyte-like cells obtained by the method according to any one of claims 3 or 7 to 8, for use in cell replacement.

26. An isolated population of cells comprising mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 5, for use in cell replacement.

27. A composition comprising at least one isolated population of mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 5 and at least one isolated population of cardiomyocyte-like cells obtained by the method according to any one of claims 3 or 7 to 8, for use in cell replacement.

28. Use of a population of mesenchymal stem cell-like cells and cardiomyocyte-like cells obtained by the method according to claim 1 or 2 for the preparation of a composition for cell replacement.

29. Use of at least one isolated population of mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 5 for the preparation of a composition for cell replacement.

30. Use of at least one isolated population of cardiomyocyte-like cells obtained by the method according to any one of claims 3 or 7 to 8 for the preparation of a composition for cell replacement.

31. Use of at least one isolated population of mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 5 and at least one isolated population of cardiomyocyte-like cells obtained by the method according to any one of claims 3 or 7 to 8 for the preparation of a composition for cell replacement.

32. A method comprising using at least one population of mesenchymal stem cell-like cells and cardiomyocyte-like cells obtained by the method according to claim 1 or 2 to replace cells.

33. A method comprising using at least one isolated population of mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 5 to replace cells.

34. A method comprising using at least one isolated population of cardiomyocyte-like cells obtained by the method according to any one of claims 3or 7 to 8 to replace cells.

35. A method comprising using at least one isolated population of mesenchymal stem cell-like cells obtained by the method according to any one of claims 3 to 5 and at least one isolated population of

cardiomycocyte-like cells obtained by the method according to any one of claims 3 or 7 to 8 to replace cells.